Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-obesity drug development.

Harold Bays1, Carlos Dujovne

  • 1L-MARC Research Center, Louisville, Kentucky 40213, USA.

Expert Opinion on Investigational Drugs
|September 13, 2002
PubMed
Summary

Obesity is a growing epidemic, and current treatments are insufficient. New anti-obesity drugs are needed to safely and effectively manage this complex metabolic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.

Obesity pillars·2026
Same author

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economics·2026
Same author

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial.

European heart journal open·2025
Same author

Editorial: Exploring the nuances of obesity in Asian populations.

Obesity pillars·2025
Same author

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

The New England journal of medicine·2024

Area of Science:

  • Metabolic disease research
  • Public health and epidemiology

Background:

  • Obesity is a global epidemic accelerating morbidity and mortality.
  • Current lifestyle interventions are largely ineffective for obesity treatment.
  • Limited availability of safe, effective, and well-tolerated anti-obesity medications.

Purpose of the Study:

  • To review the challenges and promise of developing new anti-obesity drugs.
  • To highlight the need for safe and effective pharmacological interventions for obesity management.

Main Methods:

  • Review of existing literature on obesity and anti-obesity drug development.
  • Analysis of challenges faced by investigational anti-obesity medications.
  • Discussion of the potential for future anti-obesity drugs.

Main Results:

  • Despite significant health consequences, developing effective anti-obesity drugs faces unique challenges.
  • Numerous anti-obesity drugs are currently in development with promising potential.
  • Obesity exacerbates other metabolic disorders like hypertension and diabetes.

Conclusions:

  • New anti-obesity drugs are anticipated to become as safe and effective as treatments for other metabolic disorders.
  • Addressing obesity is crucial for managing related metabolic conditions.
  • Advancements in anti-obesity pharmacotherapy are essential for public health.

Related Experiment Videos